Rivaroxaban-based antithrombotic strategy vs antiplatelet-based strategy after TAVR to optimize clinical outcomes: GALILEO

Reported from the AHA Scientific Sessions 2019 in Philadelphia - USA

Watch this short interview of Marco Valgimigli (GALILEO Trial Steering Committee) on the primary results of the GALILEO trial:

1. This is the first trial to examine the use of NOACs in TAVI. Please briefly describe the design of the trial.
2. Why was the study terminated prematurely?
3. How can we explain an increase in both bleeding & thromboembolic events in the Rivaroxaban arm?
4. In post-TAVI patients who require anticoagulation for other reasons eg atrial fibrillation, what is your current regimen of choice?

GALILEO: Global Comparison of a Rivaroxaban-based Antithrombotic Strategy Versus an Antiplatelet-based Strategy after Transcathether Aortic Valve Replacement to Optimize Clinical Outcomes

Selected in The New England Journal of Medicine: read this EAPCI/PCR Journal Club review of the GALILEO Trial

• Also watch the interview of David J Maron on the ISCHEMIA trial
• Also watch the report of M. Al Asnag and F. Costa on Impella vs. balloon pump, COLCOT, RECOVERY